Baseline characteristics of intent-to-treat set of patients who received intracameral Mydrane or standard topical regimen for cataract surgery
| Mydrane group (N=295) | Reference group (N=296) | |
|---|---|---|
| Gender | ||
| Male | ||
| n (%) | 120 (40.7) | 134 (45.3) |
| Female | ||
| n (%) | 175 (59.3) | 162 (54.7) |
| Age (years) | ||
| N | 275 | 286 |
| Mean±SD | 69.2±9.4 | 70.6±9.2 |
| Min–Max | 43–87 | 34–89 |
| Time since cataract diagnosis (months) | ||
| N | 276 | 286 |
| Mean±SD | 16.9±43.9 | 11.0±16.6 |
| Median | 4.3 | 4.0 |
| Min–Max | 0–637 | 1–112 |
| Visible iris diameter at selection | ||
| N | 286 | 287 |
| Mean±SD | 11.9±0.6 | 11.9±0.5 |
| Min–Max | 10.0–14.0 | 10.0–13.5 |
Mydrane group, patients who received an intracameral injection of a standardised combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% just after the first incision; n and N, number of patients; Reference group, patients who received a standard topical regimen of one drop each, of tropicamide 0.5% and phenylephrine 10% repeated three times at 10 min intervals beginning 30 min before surgery.